195 related articles for article (PubMed ID: 24355193)
1. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
2. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
Mutizwa MM; Berk DR; Anadkat MJ
Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
[No Abstract] [Full Text] [Related]
3. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
Wheless JW; Almoazen H
J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
[TBL] [Abstract][Full Text] [Related]
4. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
Haemel AK; O'Brian AL; Teng JM
Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
[No Abstract] [Full Text] [Related]
5. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
[No Abstract] [Full Text] [Related]
6. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
7. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
[TBL] [Abstract][Full Text] [Related]
8. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
[TBL] [Abstract][Full Text] [Related]
9. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
[TBL] [Abstract][Full Text] [Related]
10. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
11. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
12. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
13. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
[No Abstract] [Full Text] [Related]
14. Successful topical rapamycin treatment for facial angiofibromata in two children.
Pynn EV; Collins J; Hunasehally PR; Hughes J
Pediatr Dermatol; 2015; 32(3):e120-3. PubMed ID: 25790347
[TBL] [Abstract][Full Text] [Related]
15. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Arch Dermatol; 2012 Jan; 148(1):138-9. PubMed ID: 22250258
[No Abstract] [Full Text] [Related]
16. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
17. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
18. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
[TBL] [Abstract][Full Text] [Related]
19. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
